Evelo Biosciences

$11.85
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.60 (-4.82%) As of 5:26 PM UTC today

Why Robinhood?

You can buy or sell EVLO and other stocks, options, and ETFs commission-free!

About EVLO

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases; EDP2939 for inflammation; and EDP1908 for oncology.

CEO

Balkrishan Gill

Employees

Headquarters

Cambridge, Massachusetts

Founded

2014

Market Cap

535.77M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

366.23K

High Today

$12.70

Low Today

$11.80

Open Price

$12.54

Volume

164.53K

52 Week High

$19.93

52 Week Low

$3.55

EVLO News

BenzingaApr 12

Why Ikena Oncology, Evelo Biosciences And 180 Life Sciences Are Rallying Today

Ikena Oncology, Inc. (NASDAQ: IKNA), 180 Life Sciences Corp. (NASDAQ: ATNF) and Evelo Biosciences, Inc. (NASDAQ: EVLO) are among the major biopharma movers of M

Analyst Ratings

50%

of 6 ratings

Buy

50%

Hold

50%

Sell

EVLO Earnings

-$0.78

-$0.52

-$0.26

$0.00

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Estimated

— per share

Actual

Expected May 10, Pre-Market